Mirdametinib Patent Expiration
Mirdametinib was first introduced by Springworks Therapeutics Inc
Mirdametinib Patents
Given below is the list of patents protecting Mirdametinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Gomekli | US12029711 | Dosage forms of mirdametinib | Mar 15, 2044 | Springworks |
| Gomekli | US11806322 | Mirdametinib treatment | Mar 16, 2043 | Springworks |
| Gomekli | US11839595 | Mirdametinib treatment | Mar 16, 2043 | Springworks |
| Gomekli | US11883375 | Mirdametinib treatment | Mar 16, 2043 | Springworks |
| Gomekli | US12220390 | Mirdametinib treatment | Mar 16, 2043 | Springworks |
| Gomekli | US11066358 | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof | Feb 17, 2041 | Springworks |
| Gomekli | US11084780 | Door construction | Feb 17, 2041 | Springworks |
| Gomekli | US11453641 | Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | Feb 17, 2041 | Springworks |
| Gomekli | US11571402 | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof | Feb 17, 2041 | Springworks |
| Gomekli | US11806321 | Non-linear dosing of mirdametinib | Feb 17, 2041 | Springworks |
| Gomekli | US11819487 | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib | Feb 17, 2041 | Springworks |
| Gomekli | US12011424 | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib | Feb 17, 2041 | Springworks |
| Gomekli | US12037306 | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide | Feb 17, 2041 | Springworks |
| Gomekli | US12090128 | Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof | Feb 17, 2041 | Springworks |
Mirdametinib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List